Epigenomics AG (FRA:ECX)
Germany · Delayed Price · Currency is EUR 0.9000
0.00 (0.00%)
At close: Sep 18, 2026
Epigenomics AG Balance Sheet
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 0.28 | 0.41 | 0.93 | 2.1 | 7.8 | 23.05 |
Cash & Short-Term Investments | 0.28 | 0.41 | 0.93 | 2.1 | 7.8 | 23.05 |
Cash Growth | -63.74% | -55.34% | -55.94% | -73.04% | -66.14% | 409.14% |
Accounts Receivable | - | 0.01 | - | 0.3 | 0.05 | 0.07 |
Other Receivables | - | - | - | - | - | 0.13 |
Receivables | - | 0.01 | - | 0.3 | 0.05 | 0.2 |
Inventory | - | - | - | - | 0.04 | 0.18 |
Prepaid Expenses | - | - | - | - | - | 0.22 |
Other Current Assets | 0.02 | 0.02 | 0.04 | 0.08 | 0.23 | 0.06 |
Total Current Assets | 0.29 | 0.44 | 0.97 | 2.49 | 8.12 | 23.71 |
Property, Plant & Equipment | - | - | - | 0 | 0.57 | 0.89 |
Long-Term Investments | - | - | - | 2.28 | 0.79 | - |
Other Intangible Assets | - | - | - | 0.01 | 0.03 | 0.01 |
Long-Term Deferred Charges | - | - | - | - | - | 0.05 |
Other Long-Term Assets | 11.31 | 11.18 | 10.88 | 8.07 | 4.48 | - |
Total Assets | 11.6 | 11.62 | 11.85 | 12.85 | 13.99 | 24.66 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0 | - | 0.01 | 0.26 | 0.53 | 0.5 |
Accrued Expenses | - | 0.06 | 0.04 | 0.33 | 0.05 | 1.25 |
Current Portion of Long-Term Debt | - | - | - | 0.46 | - | - |
Current Portion of Leases | - | - | - | - | - | 0.09 |
Current Income Taxes Payable | 0 | 0 | 0.01 | 0.02 | 0.06 | 0.06 |
Current Unearned Revenue | - | - | - | - | - | 0.07 |
Other Current Liabilities | - | 0.01 | 0.25 | 0.35 | - | 0.17 |
Total Current Liabilities | 0.01 | 0.07 | 0.3 | 1.41 | 0.64 | 2.14 |
Long-Term Debt | 11.38 | 11.38 | 11.38 | 11.43 | 12.66 | - |
Long-Term Leases | - | - | - | - | - | 0.37 |
Other Long-Term Liabilities | 0.21 | 0.16 | 0.17 | 0.01 | 5.01 | 0.03 |
Total Liabilities | 11.6 | 11.61 | 11.85 | 12.84 | 18.31 | 2.54 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.88 | 0.88 | 0.88 | 0.85 | 4.09 | 15.54 |
Retained Earnings | -89.25 | -89.12 | -88.81 | -85.46 | -84.41 | -93.16 |
Comprehensive Income & Other | 11.3 | 88.25 | 87.93 | 84.6 | 75.99 | 99.74 |
Shareholders' Equity | - | 0 | - | - | -4.32 | 22.12 |
Total Liabilities & Equity | 11.6 | 11.61 | 11.85 | 12.84 | 13.99 | 24.66 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 11.38 | 11.38 | 11.38 | 11.89 | 12.66 | 0.46 |
Net Cash (Debt) | -11.1 | -10.97 | -10.46 | -9.79 | -4.85 | 22.59 |
Net Cash Growth | - | - | - | - | - | 487.64% |
Net Cash Per Share | -12.66 | -12.51 | -11.92 | -11.47 | -5.97 | 40.31 |
Filing Date Shares Outstanding | 0.88 | 0.88 | 0.88 | 0.85 | 0.82 | 0.78 |
Total Common Shares Outstanding | 0.88 | 0.88 | 0.88 | 0.85 | 0.82 | 0.78 |
Working Capital | 0.29 | 0.37 | 0.68 | 1.08 | 7.48 | 21.57 |
Book Value Per Share | - | 0.00 | - | - | -5.28 | 28.47 |
Tangible Book Value | - | 0 | - | -0.01 | -4.35 | 22.11 |
Tangible Book Value Per Share | - | 0.00 | - | -0.01 | -5.31 | 28.45 |
Machinery | - | - | - | 0.05 | 1.82 | 1.86 |
Leasehold Improvements | - | - | - | - | 0.85 | - |